Osimertinib
CAS 1421373-65-0
Em Estoque
Osimertinib
Cat. No. ANT-OMT-00CAS 1421373-65-0Em Estoque
Dados Técnicos
Cat. No.ANT-OMT-00
CAS1421373-65-0
Fórmula Mol.C28H33N7O2
Peso Mol.499.61 g/mol
IUPACN-[2-[2-(dimethylamino)ethyl-methylamino]-4-methoxy-5-[[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino]phenyl]prop-2-enamide
SMILESCN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC
InChIInChI=1S/C28H33N7O2/c1-7-27(36)30-22-16-23(26(37-6)17-25(22)34(4)15-14-33(2)3)32-28-29-13-12-21(31-28)20-18-35(5)24-11-9-8-10-19(20)24/h7-13,16-18H,1,14-15H2,2-6H3,(H,30,36)(H,29,31,32)
Chave InChIDUYJMQONPNNFPI-UHFFFAOYSA-N
PurezaNA
Descrição
Visão geral
Osimertinib, sold under the brand name Tagrisso, is a medication used to treat non-small-cell lung carcinomas with specific mutations. It is a third-generation epidermal growth factor receptor tyrosine kinase inhibitor.The most common side effects include diarrhea, rash, musculoskeletal pain, dry skin, skin inflammation around nails, sore mouth, fatigue and cough.Osimertinib was approved for medical use in the United States in November 2015,and in the European Union in February 2016
A Anant Labs fabrica e fornece impurezas de Osimertinib de alta qualidade para o mercado global. Nossas impurezas EP de Osimertinib são utilizadas por fabricantes de APIs e empresas farmacêuticas totalmente integradas em todo o mundo.
Sinônimos
N-[2-[[2-(Dimethylamino)ethyl]methylamino]-4-methoxy-5-[[4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl]amino]phenyl]-2-propenamideosimertinib1421373-65-0AZD-9291AZD9291MereletinibAZD 9291osimertinibumN-(2-{[2-(Dimethylamino)ethyl](Methyl)amino}-4-Methoxy-5-{[4-(1-Methyl-1h-Indol-3-Yl)pyrimidin-2-Yl]amino}phenyl)prop-2-Enamide3C06JJ0Z2O
